A very good morning from historic Bury St Edmunds in the heart of Suffolk
Some of you might have seen the multi centre trail "Trastuzumab after
Adjuvant Chemotherapy in HER2-Positive Breast Cancer" published in this
week's NEJM. Full text available @
The authors end their paper by stating "The results of this trial indicate
that one year of adjuvant trastuzumab should be considered a standard option
on completion of locoregional therapy and neoadjuvant or adjuvant
chemotherapy for women who fulfill the study eligibility criteria used in
the HERA trial".
This issue has had lot publicity in the last few weeks in the UK with a
press release from the Department of Health and a lot of media interest.
I quickly looked through the paper to find whether any NNT or NNH were
available. I could not find them in my initial reading of the paper. There
is no mention of it in the abstract. If it is there did I miss it?
If it is not there has any body done the quick stats to come out with NNT or
NNH? I think in such a topical area it would have been helpful if the NNTs
and NNHs were presented.
I would welcome your thoughts on the above.
Warm regards & very best wishes,
Dr.P.Badrinath MD, BS, M.Phil, MPH, PhD (Cantab), MFPH
Consultant in Public Health & Affiliated Clinical Lecturer,
Suffolk West PCT & University of Cambridge, UK
Disclaimer: The above views are my own and not that of my employing